Literature DB >> 7782482

The safety of concomitant use of sumatriptan and antidepressant treatments.

P Blier1, R Bergeron.   

Abstract

It is presently contraindicated to use the antimigraine drug sumatriptan with selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, or lithium. Consequently, many patients undergoing these pharmacotherapies for psychiatric disorders may not benefit from the therapeutic effect of sumatriptan in acute migraine attacks. Because sumatriptan does not appear to cross the blood-brain barrier and has a short half-life, it was deemed relatively safe to prescribe sumatriptan with antidepressant treatments. Fourteen patients receiving fluoxetine, fluvoxamine, sertraline, moclobemide, lithium, or buspirone did not experience significant side effects when they took oral sumatriptan for the relief of migraine on a total of 103 episodes. It is concluded that the combined use of sumatriptan with the above-mentioned antidepressant treatments may be safe.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7782482     DOI: 10.1097/00004714-199504000-00005

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  6 in total

Review 1.  Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review.

Authors:  S S Jhee; T Shiovitz; A W Crawford; N R Cutler
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 2.  Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders.

Authors:  N S Gunasekara; S Noble; P Benfield
Journal:  Drugs       Date:  1998-01       Impact factor: 9.546

3.  The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers.

Authors:  A D Van Haarst; J M Van Gerven; A F Cohen; M De Smet; A Sterrett; K L Birk; A L Fisher; M E De Puy; M R Goldberg; D G Musson
Journal:  Br J Clin Pharmacol       Date:  1999-08       Impact factor: 4.335

Review 4.  Drug interactions of clinical significance with selective serotonin reuptake inhibitors.

Authors:  P B Mitchell
Journal:  Drug Saf       Date:  1997-12       Impact factor: 5.606

5.  Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.

Authors:  R H Foster; K L Goa
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

6.  Paroxetine treatment and the prolactin response to sumatriptan.

Authors:  Y K Wing; E M Clifford; B D Sheehan; G M Campling; R A Hockney; P J Cowen
Journal:  Psychopharmacology (Berl)       Date:  1996-04       Impact factor: 4.530

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.